Clevidipine Effectively and Rapidly Controls Blood Pressure Preoperatively in Cardiac Surgery Patients: The Results of the Randomized, Placebo-Controlled Efficacy Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery-1
- 1 October 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Anesthesia & Analgesia
- Vol. 105 (4), 918-925
- https://doi.org/10.1213/01.ane.0000281443.13712.b9
Abstract
Clevidipine is an ultrashort-acting, third-generation IV dihydropyridine calcium channel blocker that exerts rapid and titratable arterial blood pressure reduction, with fast termination of effect due to metabolism by blood and tissue esterases. As an arterial-selective vasodilator, clevidipine reduces peripheral vascular resistance directly, without dilating the venous capacitance bed. In this randomized, double-blind, placebo-controlled multicenter trial we evaluated the efficacy and tolerability of clevidipine in treating preoperative hypertension. One-hundred-fifty-two patients scheduled for cardiac surgery with current or recent hypertension were randomized to receive clevidipine or placebo preoperatively. One-hundred-five patients met postrandomization entrance criteria (systolic blood pressure [SBP] > or =160 mm Hg after inserting an arterial catheter) for reduction by > or =15% from baseline in SBP. The patients thus received infusions of clevidipine (0.4-8.0 microg x kg(-1) x min(-1)) or 20% lipid emulsion (placebo) for at least 30 min. Treatment failure was defined as failure to reduce SBP by > or =15% from baseline or discontinuance of drug for any reason. Patients treated with clevidipine demonstrated a 92.5% rate of treatment success and a significantly lower rate of treatment failure (7.5%, 4 of 53) than patients receiving placebo (82.7%, 43 of 52; P < 0.0001). Clevidipine achieved target blood pressures (SBP reduced by > or =15%) at a median of 6.0 min (95% confidence interval 6-8 min). A modest increase in heart rate from baseline occurred during clevidipine administration. Adverse events for each treatment group were similar. Clevidipine was effective in rapidly decreasing blood pressure preoperatively to targeted blood pressure levels and was well tolerated in patients scheduled for cardiac surgery.Keywords
This publication has 21 references indexed in Scilit:
- Exploring an Optimum Intra/Postoperative Management Strategy for Acute Hypertension in the Cardiac Surgery PatientJournal of Cardiac Surgery, 2006
- Pharmacodynamic, Pharmacokinetic and Clinical Effects of Clevidipine, an Ultrashort‐Acting Calcium Antagonist for Rapid Blood Pressure ControlCardiovascular Drug Reviews, 2004
- Isolated Systolic Hypertension Is Associated with Adverse Outcomes from Coronary Artery Bypass Grafting SurgeryAnesthesia & Analgesia, 2002
- PERIOPERATIVE CARDIAC COMPLICATIONSMedical Clinics of North America, 2001
- Perioperative blood pressure control: A prospective survey of patient management in cardiac surgeryJournal of Cardiothoracic and Vascular Anesthesia, 2000
- Treatment of Hypertension in the Perioperative PatientAnnals of Pharmacotherapy, 2000
- Incidence and aetiology of perioperative hypertensionActa Anaesthesiologica Scandinavica, 1993
- The ideal agent for perioperative hypertension and potential cytoprotective effectsActa Anaesthesiologica Scandinavica, 1993
- Perioperative hypertensionCoronary Artery Disease, 1993
- Systemic arterial hypertension associated with cardiac surgeryThe American Journal of Cardiology, 1980